Arcturus Therapeutics To Present Overview Of ARCT-810 Phase 2 Clinical Program For Ornithine Transcarbamylase Deficiency And Arcturus’ mRNA Liver Therapeutics Platform On Sept. 23

Loading news article.

Arcturus Therapeutics To Present Overview Of ARCT-810 Phase 2 Clinical Program For Ornithine Transcarbamylase Deficiency And Arcturus’ mRNA Liver Therapeutics Platform On Sept. 23 | WAPE

Arcturus Therapeutics To Present Overview Of ARCT-810 Phase 2 Clinical Program For Ornithine Transcarbamylase Deficiency And Arcturus’ mRNA Liver Therapeutics Platform On Sept. 23

Article summary

Related companies

Analyzed by WAPE AI.

Comments —